68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

NCT ID: NCT04716725

Last Updated: 2024-10-16

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-28
• Study Completion Date: 2025-04-30

Brief Summary

This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block androgen production (castration resistant), and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent that may help get more detailed pictures of the tumor. This trial aims to see whether using 68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the body.

Detailed Description

PRIMARY OBJECTIVE:

I. To determine whether the percent change from baseline to 16 weeks (+/- 8 weeks) in maximum standard uptake value (SUVmax) averaged across up to 16 lesions per patient (SUVmax-ave) is associated with >= 50% decline from baseline in serum prostate specific antigen (PSA50) response.

SECONDARY OBJECTIVES:

I. To determine whether the percent change from baseline in SUVmax-ave on PSMA PET is associated with time-to-event endpoints including PSA progression-free survival and overall survival.

II. To determine whether the percent change from baseline in SUVmax on PSMA PET is associated with objective response by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 on a per-lesion basis among measurable soft tissue lesions present at baseline.

EXPLORATORY (CORRELATIVE) OBJECTIVES:

I. To descriptively characterize the histologic, transcriptional, and genomic features of PSMA low/negative lesions among patients who undergo paired optional metastatic tumor biopsy.

II. To descriptively characterize the relationship between SUVmax-ave on baseline Ga-PSMA PET with optional baseline fludeoxyglucose F-18 (FDG)-PET.

III. To determine whether heterogeneity of PSMA expression on baseline Ga-PSMA PET is associated with overall survival.

IV. To descriptively characterize the patterns of PSMA expression at the time of disease progression among patients who undergo optional PSMA PET.

V. To determine whether the percent change from baseline in PSMA PET is associated with PSA50 response among subgroups of patients defined by treatment modality received, including androgen receptor (AR) targeting treatment, PSMA-targeting radioligand therapy, cytotoxic chemotherapy, and immunotherapy.

OUTLINE:

Patients receive gallium Ga 68-PSMA-11 intravenously (IV) and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.

After progression or study completion, patients are followed up every 3 months for up to 24 months

Conditions

Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Experimental (68Ga-PSMA-11 PET)

Patients receive gallium 68Ga-PSMA-11 IV and undergo PET at baseline, 16 weeks after initiating therapy, and at time of disease progression.

Group Type: EXPERIMENTAL

68Ga-PSMA-11

Intervention Type: DRUG

Given IV

Positron Emission Tomography (PET)

Intervention Type: PROCEDURE

Undergo PET

Interventions

68Ga-PSMA-11

Given IV

Intervention Type: DRUG

Positron Emission Tomography (PET)

Undergo PET

Intervention Type: PROCEDURE

Other Intervention Names

68Ga Prostate-specific Membrane Antigen (PSMA) 11; Gallium Ga-68 gozetotide; Gallium-68 PSMA; Gallium Ga 68 PSMA-11; Gallium Ga 68-labeled PSMA-11; PET; PET Scan

Eligibility Criteria

Inclusion Criteria

1. Sub-cohort A1: Patients must have baseline evaluations performed within 12 weeks prior to the start of systemic therapy.

2. Sub-cohort A2: Patients must meet all the following requirements:

• Have had a baseline pre-treatment 68Ga-PSMA-11 PET scan and PSA measurement performed within 12 weeks prior to the start of current systemic therapy.
• Able to have an on-treatment 68Ga-PSMA-11 PET and a PSA measurement within 16 weeks (+/- 8 weeks) after the start of current systemic therapy.

Note: The screening period for sub-cohort A2 is within 24 weeks after the patient started their current systemic therapy.

3. Patients must have progressive castration resistant prostate cancer, according to PCWG3 criteria.

4. Patients must have planned initiation of systemic treatment (sub-cohort A1), or ongoing systemic treatment (sub-cohort A2) for castration resistant prostate cancer within 12 weeks of baseline Ga-PSMA PET.

5. Patients must have at least one metastatic lesion with PSMA uptake at or above the blood pool on their baseline PSMA PET scan.

6. The patient must be able and willing to comply with study procedures and provide signed and dated informed consent.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Patient must be Aged 18 years or older at the time of study entry.

9. Patients who undergo optional metastatic tumor biopsy following completion of baseline Ga-PSMA PET must additionally meet all of the following criteria:

• Presence of one or more metastases by standard radiographic scans that is safely accessible to tumor biopsy in the judgment of treating clinician and/or Interventional Radiology.
• No history of radiation therapy to the target metastatic lesion selected for tumor biopsy.
• No contra-indication to biopsy including uncontrolled bleeding diathesis.
• Platelets > 75,000/ul and prothrombin time (PT) or institution normalized ratio (INR) and a partial thromboplastin time (PTT) < 1.5 times the institutional upper limit of normal (ULN) within 14 days prior to biopsy.

Exclusion Criteria

1. Patients who because of age, general medical or psychiatric condition, or physiologic status cannot give valid informed consent.

2. Patients with any condition that, in the opinion of the Principal Investigator, would impair the patient's ability to comply with study procedures.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Conquer Cancer Foundation

OTHER

Sponsor Role: collaborator

Gateway for Cancer Research

OTHER

Sponsor Role: collaborator

Prostate Cancer Foundation

OTHER

Sponsor Role: collaborator

Thomas Hope

OTHER

Sponsor Role: lead

Responsible Party

Thomas Hope

Co-Principal Investigator (IND Holder)

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Ivan A de Kouchovsky, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

University of California San Francisco

San Francisco, California, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

NCI-2020-13741

Identifier Type: REGISTRY

Identifier Source: secondary_id

209211

Identifier Type: -

Identifier Source: org_study_id